Navigation Links
Risk of colon cancer to be assessed by simple blood test

Colon cancer is the second most common forms of cancer, and is associated with a significant mortality. There is no single cause for colon cancer. The presence of benign growths in the colon, family history// of colon cancer, and dietary factors are some of the factors that predispose to colon cancer. The disease is completely treatable if diagnosed early.

Researchers are now trying to develop a practical test to predict a person's risk of colon cancer by looking for a particular biological marker in the blood. If successful, the test could be broadly applied to identify those who most need to be monitored with invasive but standard colonoscopy or who should make changes in their diet or in other factors to help lower their risk of developing colon cancer.

It has been suspected that genomic changes underlie cancer risk. The BRCA1 and BRCA2 genes implicated in breast and ovarian cancers are great examples, but they are applicable only to a small percentage -- less than one percent -- of women. The knowledge hasn't been translated yet into a broadly applicable way to identify individuals most at risk.

The changes associated with IGF-2 levels are linked to epigenetic mechanisms- changes in what is attached to genetic material. An epigenetic process called “imprinting normally controls the IGF-2 gene" in which the level of protein production proteins on which parent the copy came from.

For IGF-2, only the gene copy inherited from the father should be turned on, and that from the mother should be off. In about five percent to 10 percent of people, however, both copies of the gene are turned on -- a problem called loss of imprinting, leading to cancer formation.

The attempt is based on the fact that five percent to 10 percent of people have improper control of a growth-promoting gene called insulin-like growth factor 2 or IGF-2. It has been regarded that increased levels pf this protein is associated with the initia
'"/>




Page: 1 2

Related medicine news :

1. Radiotherapy helps in colon cancer
2. Benefit of colonoscopy
3. Hydroxyurea derivatives kill colon cancer cells
4. Wheat wards off colon cancer
5. Defeating colon cancer
6. Calcium reduces colon cancer risk
7. Smoking risk precedes colon cancer
8. Implication of virus in colon cancer
9. New virtual colonoscopy procedure for easier colon screening
10. Long-term use of calcium supplements to prevent colon cancer
11. Aspirin may reduce he risk of colon cancer
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute 54884 1Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute 54884 2Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute 54884 3Reliv Walk for the Mission Raises Approximately 2447 000 for Malnourished People 54882 1Reliv Walk for the Mission Raises Approximately 2447 000 for Malnourished People 54882 2N2Care Unveils Backyard Smart MEDcottage 54880 1N2Care Unveils Backyard Smart MEDcottage 54880 2
Other Medicine Technology:Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 2Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 3Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 4Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 5Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 6Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 7Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 2Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 3Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 4